474677-87-7

Upstream product

• 1441379-49-2 C₁₄H₁₈O₃Si 
• 111758-60-2 methyl (3-iodophenoxy)acetate 
• 626-02-8 3-Iodophenol 

Downstream Products

• 1441379-19-6 methyl 2-(3-((2,2-fimethyl-4-oxo-7-(4-(trifluoromethoxy)phenyl)-4H-[1,3]dioxino[5,4-f ]benzofuran-6-yl)ethynyl)phenoxy)acetate 
• 1404435-65-9 3-((3-(carboxymethoxy)phenyl)ethynyl)-6-hydroxy-2-(4-(trifluoromethoxy)phenyl)benzofuran-5-carboxylic acid 
• 1441379-70-9 methyl 2-(3-((7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-6-yl)ethynyl)phenoxy)acetate 
• 1441379-76-5 methyl 2-(4-((7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-6-yl)ethynyl)-phenoxy)acetate 
• 1441379-82-3 methyl 2-(3-(6-iodo-2,2-dimethyl-4-oxo-4H-[1,3]dioxino[5,4-f ]-benzofuran-7-yl)phenoxy)acetate 
• 1441379-94-7 methyl 2-(3-(6-((3-chlorophenyl)ethynyl)-2,2-dimethyl-4-oxo-4H-[1,3]dioxino[5,4-f ]benzofuran-7-yl)phenoxy)acetate 
• 1404435-75-1 2-(3-(carboxymethoxy)phenyl)-3-((3-chlorophenyl)ethynyl)-6-hydroxybenzofuran-5-carboxylic acid 
• 1441379-88-9 methyl 2-(4-(6-iodo-2,2-dimethyl-4-oxo-4H-[1,3]dioxino[5,4-f ]-benzofuran-7-yl)phenoxy)acetate 
• 1441379-99-2 methyl 2-(4-(6-((3-chlorophenyl)ethynyl)-2,2-dimethyl-4-oxo-4H-[1,3]dioxino[5,4-f ]benzofuran-7-yl)phenoxy)acetate 
• 1404435-76-2 2-(4-(carboxymethoxy)phenyl)-3-((3-chlorophenyl)ethynyl)-6-hydroxybenzofuran-5-carboxylic acid 

Relevant academic research and scientific papers

Does targeting Arg98 of FimH lead to high affinity antagonists?

Bacterial resistance has become an important challenge in the treatment of urinary tract infections. The underlying resistance mechanisms can most likely be circumvented with an antiadhesive approach, antagonizing the lectin FimH located at the tip of fim

A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases

Lymphoid-specific tyrosine phosphatase (LYP), a member of the protein tyrosine phosphatase (PTP) family of signaling enzymes, is associated with a broad spectrum of autoimmune diseases. Herein we describe our structure-based lead optimization efforts with